STAAR Surgical (NASDAQ:STAA) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its stake in shares of STAAR Surgical (NASDAQ:STAA) by 1.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 529,218 shares of the medical instruments supplier’s stock after selling 7,402 shares during the quarter. Ensign Peak Advisors Inc owned about 1.08% of STAAR Surgical worth $25,196,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Cape Investment Advisory Inc. acquired a new position in shares of STAAR Surgical during the fourth quarter valued at approximately $42,000. GAMMA Investing LLC grew its position in STAAR Surgical by 313.9% in the first quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 992 shares during the last quarter. Covestor Ltd grew its position in STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after buying an additional 754 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical in the second quarter worth approximately $129,000. Finally, Larson Financial Group LLC acquired a new position in STAAR Surgical in the second quarter worth approximately $130,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Stock Down 3.8 %

Shares of NASDAQ:STAA opened at $30.39 on Monday. The firm has a fifty day moving average of $36.26 and a two-hundred day moving average of $40.46. The firm has a market capitalization of $1.49 billion, a P/E ratio of 98.03 and a beta of 0.58. STAAR Surgical has a 12-month low of $26.66 and a 12-month high of $52.68.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $95.22 million. STAAR Surgical had a net margin of 4.99% and a return on equity of 5.60%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the business earned $0.23 EPS. Equities research analysts expect that STAAR Surgical will post 0.17 earnings per share for the current fiscal year.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Arthur C. Butcher acquired 1,315 shares of STAAR Surgical stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $37.99 per share, with a total value of $49,956.85. Following the purchase, the director now owns 4,208 shares in the company, valued at $159,861.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

STAA has been the topic of several recent research reports. Morgan Stanley lowered shares of STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $50.00 to $37.00 in a research report on Monday, July 15th. Canaccord Genuity Group decreased their price target on shares of STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a research report on Thursday, August 8th. BTIG Research lifted their price target on shares of STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $45.57.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.